期刊文献+

瑞舒伐他汀和阿托伐他汀联合规律运动对冠心病患者动脉硬化的影响 被引量:8

下载PDF
导出
摘要 目的通过运用瑞舒伐他汀和阿托伐他汀联合规律运动治疗冠心病,观察冠心病患者动脉硬化变化并探讨可能作用机制。方法将28例冠心病患者随机分为瑞舒伐他汀组和阿托伐他汀组,分别给予相应药物治疗同时指导患者规律运动20周,治疗前后分别检测患者血压、臂踝脉搏波速度(ba PWV)、LDL-C、hs-CRP和外周血淋巴细胞和嗜酸性细胞数等指标;采用相关性分析患者ba PWV变化和LDL-C、hs-CRP以及嗜酸性细胞数变化之间的关系。结果 2组患者ba PWV均有明显下降(P<0.05或<0.01),但瑞舒伐他汀组改善更为显著(P<0.05);瑞舒伐他汀组治疗后患者嗜酸性细胞下降明显,差异有统计学意义(P<0.05);2组患者治疗后血清中LDL-C与hs-CRP含量均较治疗前下降,瑞舒伐他汀组下降幅度大于阿托伐他汀组,差异有统计学意义(P<0.05);2组患者ba PWV变化与嗜酸性细胞数变化呈正相关(P<0.05)。结论他汀类药物联合规律运动可以改善冠心病患者动脉硬化,且这种变化与外周血嗜酸性细胞减少密切相关,提示嗜酸性细胞可能通过介导免疫反应参与动脉粥样硬化病理过程。
作者 宋宇新
出处 《河北医药》 CAS 2016年第4期511-513,共3页 Hebei Medical Journal
  • 相关文献

参考文献11

  • 1Goel K, Lennon RJ, Tilbury RT, et al. Impact of cardiac rehabilitation on mortality and cardiovascular events after pereutaneous coronary inter- vention in the community. Circulation,2011,123: 2544-2352.
  • 2LaRosa JC, Grundy SM, Waters DD, et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. New England Jour- nal of Medicine ,2005,352 : 1425-1435.
  • 3Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. The American Journal of Medicine ,2004, 116 : 682-692.
  • 4Toyama K, Sugiyama S, Oka H, et al. Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant in- crease in high-density lipoprotein cholesterol in patients with coronary ar- tery disease. Atherosclerosis ,2011,217 : 158-164.
  • 5Sugawara J, Hayashi K, Yokoi T, et al. Brachial-ank!e pulse wave veloci- ty : An index of central arterial stiffness. Hum Hypertens, 2005,19 : 401 - 406.
  • 6Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Non- invasive Investigation of Large Arteries. Expert consensus document on ar- terial stiffness: Methodological issues and clinical applications. Eur Heart,2006,27 : 2588-2605.
  • 7Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a thera- peutic target: A systematic review. JA1VIA,2007 ,298 :786-798.
  • 8Marun DJ,Fazio S, Lintan MF. Current perspectives on statins. Circula- tion,2011,101 : 207-213.
  • 9Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease-a perspective. Drug Des Dev- el Ther,2010,4 : 383-413.
  • 10Libby P, Shi GP. Mast ceils as mediators and modulators of atherogene- sis. Circulation ,2007,115 : 2471-2473.

同被引文献45

引证文献8

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部